Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.32%
1,100.57
-3.53
-0.32%
—1,104.101,103.921,108.751,097.16——
SIXC
Communications
SIXC
Communications
SIXC
+0.16%
605.15
+0.99
+0.16%
—604.16604.16610.19604.12——
SIXE
Energy
SIXE
Energy
SIXE
-0.22%
1,195.19
-2.62
-0.22%
—1,197.811,200.581,213.071,192.02——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.03%
1,739.91
-0.50
-0.03%
—1,740.411,739.551,750.271,730.60——
SIXM
Financials
SIXM
Financials
SIXM
+0.65%
638.56
+4.12
+0.65%
—634.44633.13639.87633.01——
SIXR
Staples
SIXR
Staples
SIXR
-1.11%
831.57
-9.33
-1.11%
—840.90839.53841.73831.10——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.82%
213.36
-1.77
-0.82%
—215.13215.13215.85213.24——
SIXT
Technology
SIXT
Technology
SIXT
+0.17%
3,234.18
+5.47
+0.17%
—3,228.713,225.623,235.433,198.95——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.02%
935.65
-0.22
-0.02%
—935.87938.37942.00935.65——
SIXV
Health care
SIXV
Health care
SIXV
-0.54%
1,449.26
-7.86
-0.54%
—1,457.121,452.741,466.881,449.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,382.45
-17.39
-0.72%
—2,399.842,389.712,394.612,371.22——
471A:FRA
aTyr Pharma Inc
€0.57
-1.39%
(-0.0080) 1D
Apr 27, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 471A...
Open
€0.57
High
€0.57
Low
€0.57
Mkt. cap
77.07M
Avg. vol.
0.00
Volume
0.00
52-wk high
€5.70
52-wk low
€0.47
No. of employees
59
News stories
From sources across the web
Profile
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
About aTyr Pharma Inc
CEO-
Employees59
FoundedJan 1, 2005
Headquarters-
SectorBiotechnology
Websiteatyrpharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
190.00K
-
Cost of goods sold
11.81M
15.38M
22.13M
10.89M
Cost of revenue
11.81M
15.38M
22.13M
10.89M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.96M
4.93M
4.80M
3.90M
Operating expense
3.96M
4.93M
4.80M
3.90M
Total operating expenses
15.77M
20.31M
26.94M
14.80M
Operating income
-15.77M
-20.31M
-26.74M
-14.80M
Other non operating income
892.00K
781.00K
999.00K
832.00K
EBT including unusual items
-14.88M
-19.53M
-25.75M
-13.96M
EBT excluding unusual items
-14.88M
-19.53M
-25.75M
-13.96M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.88M
-19.53M
-25.74M
-13.96M
Net profit margin
-
-
-13,549.47%
-
Earnings per share
-0.17
-0.22
-0.26
-0.14
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.61M
-20.15M
-26.58M
-14.63M
Gain or loss from assets sale
-
-
-
-12.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer